Collegium Pharmaceutical (NASDAQ:COLL) Now Covered by Analysts at Barclays

Barclays initiated coverage on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a research report released on Monday morning, MarketBeat reports. The firm issued an overweight rating and a $58.00 price objective on the specialty pharmaceutical company’s stock.

Several other equities research analysts have also commented on COLL. Needham & Company LLC reissued a “buy” rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a report on Tuesday, October 28th. Truist Financial boosted their target price on shares of Collegium Pharmaceutical from $45.00 to $48.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Weiss Ratings raised shares of Collegium Pharmaceutical from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday. Wall Street Zen upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, Zacks Research raised Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 21st. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $47.00.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL traded up $0.24 during trading on Monday, reaching $47.27. 14,243 shares of the company’s stock traded hands, compared to its average volume of 398,001. The company has a quick ratio of 1.27, a current ratio of 1.36 and a debt-to-equity ratio of 2.71. Collegium Pharmaceutical has a fifty-two week low of $23.23 and a fifty-two week high of $49.09. The company has a 50-day simple moving average of $39.86 and a 200-day simple moving average of $35.61. The firm has a market cap of $1.49 billion, a PE ratio of 29.48 and a beta of 0.61.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share (EPS) for the quarter. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%.The company had revenue of $135.55 million for the quarter. As a group, analysts predict that Collegium Pharmaceutical will post 5.62 earnings per share for the current year.

Insider Buying and Selling at Collegium Pharmaceutical

In related news, CFO Colleen Tupper sold 30,000 shares of the business’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $40.53, for a total value of $1,215,900.00. Following the sale, the chief financial officer owned 126,667 shares in the company, valued at approximately $5,133,813.51. The trade was a 19.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Rita J. Balice-Gordon sold 3,650 shares of the stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $47.03, for a total value of $171,659.50. Following the completion of the sale, the director directly owned 52,629 shares in the company, valued at $2,475,141.87. This represents a 6.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 2.51% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Collegium Pharmaceutical in the first quarter valued at $3,085,000. Nuveen LLC acquired a new stake in shares of Collegium Pharmaceutical in the 1st quarter worth $2,674,000. Public Sector Pension Investment Board raised its stake in shares of Collegium Pharmaceutical by 26.7% during the 1st quarter. Public Sector Pension Investment Board now owns 102,246 shares of the specialty pharmaceutical company’s stock worth $3,052,000 after buying an additional 21,562 shares in the last quarter. Tejara Capital Ltd lifted its stake in shares of Collegium Pharmaceutical by 288.4% in the first quarter. Tejara Capital Ltd now owns 111,792 shares of the specialty pharmaceutical company’s stock valued at $3,337,000 after purchasing an additional 83,011 shares during the period. Finally, Brandywine Global Investment Management LLC boosted its position in Collegium Pharmaceutical by 13.7% during the first quarter. Brandywine Global Investment Management LLC now owns 114,763 shares of the specialty pharmaceutical company’s stock worth $3,426,000 after purchasing an additional 13,792 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.